Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PTGX News 10 October 2025 - 11 October 2025

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership & Culture: President
11 October 2025
·······
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonistreuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeuticsreuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration dealreuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early confidence in the
10 October 2025
·····

Stock Market Today

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

7 February 2026
Macquarie Group shares fell 2.17% to A$207.83 Friday, marking a third straight decline as the ASX 200 slid 2%. Australia’s regulator trimmed liquidity requirements for Macquarie Bank after improvements in controls. Macquarie Asset Management announced two UK utility deals, including full ownership of Last Mile Infrastructure and the purchase of Energy Assets Group. Investors await Tuesday’s operational briefing.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:04 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Go toTop